Jeremy Bookman
Psychiatric/Mental Health · Seabrook, NHNPI 1427394089
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,110 of the $73,790 with a category attached, or 65.2%. Johnson & Johnson accounts for 89.9% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2024 at $21,866 and has fallen 55.0% since, to $9,841 in 2025. Among psychiatric/mental health clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 439 payments — averaging $168.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$66K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- Lundbeck LLC$808
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$802
- Axsome Therapeutics, Inc.$772
- plus $3K from 10 others
What the payments were for
- Consulting fees$7,67010%
- Speaking & faculty fees$48,11065%
- Travel & lodging$6,2438%
- Food & beverage$11,52616%
- Education$2400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 159 | $66,316 |
| Neurocrine Biosciences, Inc. | 41 | $1,264 |
| Alkermes, Inc. | 32 | $1,008 |
| Lundbeck LLC | 43 | $808 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $802 |
| Axsome Therapeutics, Inc. | 23 | $772 |
| Otsuka America Pharmaceutical, Inc. | 29 | $685 |
| Avanir Pharmaceuticals, Inc. | 18 | $558 |
| Vanda Pharmaceuticals Inc. | 32 | $495 |
| Teva Pharmaceuticals USA, Inc. | 15 | $389 |
| E.r. Squibb & Sons, L.L.C. | 8 | $246 |
| AbbVie | 6 | $209 |
| Sunovion Pharmaceuticals Inc. | 9 | $145 |
| Collegium Pharmaceutical, Inc. | 3 | $54 |
| Tempus AI, Inc | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$62,678
- INVEGA TRINZA$62,181
- LYBALVI$1,327
- SPRAVATO$590
- Auvelity$474
- ARISTADA$461
- INGREZZA$385
- CAPLYTA$130
- VRAYLAR$120
- REXULTI$116
- ARISTADA INITIO$115
- AUSTEDO$113
- VIVITROL$112
- NUEDEXTA$105
How this compares
$73,790 in reported general payments places this provider in the 95th percentile of 264 psychiatric/mental health providers in New Hampshire.
See all psychiatric/mental health providers in New Hampshire →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 25 | $190,858 |
| Invega SustennaPaliperidone Palmitate | 12 | $43,861 |
| Divalproex Sodium ErDivalproex Sodium | 430 | $15,235 |
| Aripiprazole | 161 | $11,442 |
| Divalproex Sodium | 152 | $10,469 |
| Paliperidone ErPaliperidone | 81 | $9,101 |
| Oxcarbazepine | 152 | $6,826 |
| Trazodone Hcl | 480 | $6,505 |
| Olanzapine | 344 | $6,072 |
| Gabapentin | 200 | $5,779 |
| BelsomraSuvorexant | 12 | $5,577 |
| Risperidone | 329 | $5,276 |
| Quetiapine Fumarate | 316 | $5,221 |
| Chlorpromazine Hcl | 29 | $5,122 |
| Ziprasidone Hcl | 82 | $4,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,264 | $190,85825 claims |
| Johnson & JohnsonInvega Sustenna | $66,316 | $43,86112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 264 psychiatric/mental health providers in New Hampshire.
Other psychiatric/mental health in Seabrook
- Jessica BookmanSeabrook$11K
- Jennifer GanemLondonderry$158K
- Craig IannottiManchester$146K
- Michael ScottManchester$48K
- Lisa WeldonBedford$17K
- Karin RaabergMont Vernon$14K
- Chengping WangNashua$11K
- Elizabeth LynchExeter$6K
- Tasha HumphreysExeter$6K
- Hallick LehmannLaconia$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.